

Michael E. Furrow Ph.D.

Partner

The Grace Building
1114 Avenue of the Americas, New York, NY USA 10036
t 212.775.8734 | f 212.898.1102
mfurrow@kilpatricktownsend.com

Services

Adversarial Patent ProsecutionSM
Asset Creation - Prosecution &
Counseling
Life Sciences Patent Disputes
FDA Regulation
Intellectual Property
ITC Section 337
Licensing, Transactions &
Monetization
Market Protection - Opinions &
Dispute Avoidance
Patent Due Diligence
Patent Litigation
Patents
Post-Grant Proceedings

Industries

Chemicals
Health & Life Sciences
Medical & Surgical Devices



Mike Furrow is a former medicinal chemist who counsels life sciences innovators on all aspects of patent and related regulatory strategy from the early discovery stages through product launch and evolution. His clients range from nascent startups to venerable global biopharma companies. With a focus on disputes, Mike has handled patent actions in federal courts and before the U.S. Patent and Trademark Office concerning more than a dozen small molecule drugs, as well as antibody medicines, genetically modified organisms, and various other laboratory tools and techniques. Mike's background as a chemist affords him an intimate understanding of the challenges innate to the discovery of new medicines, and clients value his resulting drive to help them explore creative ways to maximize market exclusivities.

Combining his technical prowess with his litigation mindset, Mike is known for exhaustively exploring the facts and pushing the envelope on merits strategy. He engages with the technology at a level that permits him to develop strong relationships with inventors, scientific officers, technical experts and, ultimately, the fact-finder.

Mike has authored several peer-reviewed scientific articles in preeminent chemistry journals concerning novel

stereoselective synthetic, bond-forming, and redox methods for use in the synthesis of complex molecules and was the recipient of research grants from the American Chemical Society and National Science Foundation. Mike also briefly worked as a bench chemist conducting drug discovery at a leading biotechnology company that focuses on therapies for viral infections and liver diseases. He is listed in the 2021 and 2022 editions of *IAM Strategy 300: The World's Leading IP Strategists*, has been recognized repeatedly in the New York Metro edition of *Super Lawyers* magazine, and is a regular author for *LexisNexis Practical Guidance*® and other topical publications.

Experience

Defending a pharmaceutical company in a patent action filed by a non-practicing patent holder concerning the client's commercial drug product.

Defending a nutraceutical company in a patent and contract dispute filed by a competitor.

Counseling a biotechnology startup on all IP needs.

Counseling a pharmaceutical company on portfolio strategy for COVID-19 therapeutics.

Counseling a pharmaceutical company on IP and regulatory strategy for an antiviral drug.

Represented a pharmaceutical company in Hatch-Waxman litigations concerning a drug for early onset childhood epilepsy.

Represented a pharmaceutical company in Hatch-Waxman litigations concerning a drug for treatment of opioid-induced constipation.

Counseled a pre-commercial biopharmaceutical company on portfolio strategy and development partnerships.

*Represented two major pharmaceutical companies and a university in Hatch-Waxman litigations concerning a blockbuster prostate cancer drug.

*Represented a leading research university in connection with various adversarial patent actions in the DNA sequencing space.

*Represented a major biopharma company in Hatch-Waxman litigations concerning a drug for a rare metabolic disease.

*Counseled a major pharmaceutical company on patent infringement exposure prior to launch of a now-blockbuster cancer drug.

*Represented two major life sciences companies in Hatch-Waxman litigations concerning a blockbuster

antibiotic drug.

*Counseled a major pharmaceutical company in connection with potential acquisition of a patent portfolio covering an ovarian cancer drug.

*Represented a major biotechnology company in litigation concerning genetically modified animals useful for identifying antibody therapies.

*Counseled a major life science company on scientific experiments to support a citizen petition to the Food and Drug Administration seeking heightened standards for demonstrating bioequivalence to reference antibiotic drug.

*Represented two major pharmaceutical companies in Hatch-Waxman litigations concerning a blockbuster drug product for GI disorders.

*Counseled a major biopharma company in connection with various reexaminations of patents concerning a blockbuster antithrombotic drug.

*Represented a major biotechnology company in Hatch-Waxman litigations concerning a hyperparathyroidism drug.

*Counseled a major pharmaceutical company in connection with potential acquisitions of other life science companies.

*Represented a major pharmaceutical company and a university in Hatch-Waxman litigations concerning various blockbuster antiviral drugs.

*Experience gained by attorney prior to joining Kilpatrick Townsend

Education

Harvard University J.D. (2007)

Harvard University Ph.D. (2004) Chemistry, *National Science Foundation Fellow*

Harvard College A.B. (1999) Chemistry, *summa cum laude*, *Phi Beta Kappa*, *American Chemical Society Research Grantee*

Admissions

New York (2008)

Court Admissions



U.S. Court of Appeals for the Federal Circuit

U.S. District Court for the Eastern District of New York

U.S. District Court for the Southern District of New York

Professional & Community Activities

New York Intellectual Property Law Association, Member

Federal Circuit Bar Association, Member

Insights

[News Releases](#)

Six Kilpatrick Townsend Attorneys Earn Listing in IAM Strategy 300 Global Leaders 2022

January 13, 2022

[News Releases](#)

Kilpatrick Townsend Continues Expansion of Patent Litigation Team

October 19, 2021

[Publication](#)

Patent Eligibility: Overcoming Early Litigation Challenges

September 1, 2021

[Publication](#)

Biosimilars and the Biologics Price Competition and Innovation Act (BPCIA)

February 25, 2021

[Publication](#)

Legislative Update: Incentivizing Discovery and Development Investment into Novel Antimicrobial Drugs

February 25, 2021